Literature DB >> 28929236

[Criteria for treating MRSA in sputum].

J Lorenz1, M Unnewehr2, B Schaaf2, S Gatermann3.   

Abstract

Methicillin-resistant strains of Staphylococcus aureus (MRSA) are of particular significance for the management of patients with airway infections, since the disease course is often complicated and treatment rendered difficult by multiple resistance. Their prevalence is now slowly declining, but still alarmingly high. Hospital-acquired infections are predominant, but hospital-associated and community-acquired infections do occur, as do rare infections with livestock-acquired strains. Non-nosocomial strains are characterized by different pathogenic factors and a different spectrum of antibacterial resistance; they often have a threatening disease course. Anti-infectives with activity against MRSA are unusual and have particular toxicity profiles. On the other hand, MRSA colonization is eliminated spontaneously in healthy people and acute bronchitis is treatable by common oral antibiotics. However, chronic airway infection in bronchiectasis and other forms of structural airway damage requires a complex systemic and local treatment approach for pathogen elimination.

Entities:  

Keywords:  Chronic bronchitis; Methicillin-resistant Staphylococcus aureus; Pneumonia; Respiratory tract diseases; Respiratory tract infections

Mesh:

Substances:

Year:  2017        PMID: 28929236     DOI: 10.1007/s00108-017-0328-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  14 in total

Review 1.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.

Authors:  Tobias Welte; Mathias W Pletz
Journal:  Int J Antimicrob Agents       Date:  2010-08-17       Impact factor: 5.283

Review 3.  [New antibacterial agents on the market and in the pipeline].

Authors:  W V Kern
Journal:  Internist (Berl)       Date:  2015-11       Impact factor: 0.743

Review 4.  Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Authors:  David K H Lo; Matthew N Hurley; Marianne S Muhlebach; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2015-02-24

5.  A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Authors:  J Stuart Elborn; David E Geller; Douglas Conrad; Shawn D Aaron; Alan R Smyth; Rainald Fischer; Eitan Kerem; Scott C Bell; Jeffery S Loutit; Michael N Dudley; Elizabeth E Morgan; Donald R VanDevanter; Patrick A Flume
Journal:  J Cyst Fibros       Date:  2015-01-13       Impact factor: 5.482

6.  [Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S-3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy].

Authors:  K Dalhoff; M Abele-Horn; S Andreas; T Bauer; H von Baum; M Deja; S Ewig; P Gastmeier; S Gatermann; H Gerlach; B Grabein; G Höffken; W V Kern; E Kramme; C Lange; J Lorenz; K Mayer; I Nachtigall; M Pletz; G Rohde; S Rosseau; B Schaaf; R Schaumann; D Schreiter; H Schütte; H Seifert; H Sitter; C Spies; T Welte
Journal:  Pneumologie       Date:  2012-12-06

7.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

8.  Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991.

Authors:  A L Panlilio; D H Culver; R P Gaynes; S Banerjee; T S Henderson; J S Tolson; W J Martone
Journal:  Infect Control Hosp Epidemiol       Date:  1992-10       Impact factor: 3.254

9.  Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study.

Authors:  Matthias Kappler; Felicitas Nagel; Maria Feilcke; Carolin Kröner; Ingo Pawlita; Susanne Naehrig; Jan Ripper; Meike Hengst; Ulrich von Both; Maria Forstner; Andreas Hector; Matthias Griese
Journal:  Pediatr Pulmonol       Date:  2016-07-05

10.  Efficacy of the decolonization of methicillin-resistant Staphylococcus aureus carriers in clinical practice.

Authors:  N Sai; C Laurent; H Strale; O Denis; B Byl
Journal:  Antimicrob Resist Infect Control       Date:  2015-12-18       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.